DC
ADAP

Diametric Capital’s Adaptimmune Therapeutics ADAP Stock Holding History

Diametric Capital’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-78,441
Closed -$72.6K – 335
2023
Q2 		$72.6K Buy
+78,441
New +$93.5K 0.03% 296

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Diametric Capital's ADAP Position: Q3 2023 in Review

Diametric Capital sold out of Adaptimmune Therapeutics (ADAP) in Q3 2023, closing a stake of 78,441 shares — an estimated $72.6K sold.

Diametric Capital first reported a position in ADAP in Q2 2023 and held it in 1 quarter. The position peaked at $72.6K in Q2 2023. 79 funds tracked by Wall St. Rank hold ADAP as of Q3 2023.

  • Diametric Capital reported no remaining Adaptimmune Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Diametric Capital sold 78,441 Adaptimmune Therapeutics shares in Q3 2023, an estimated $72.6K.
  • Diametric Capital first reported a position in Adaptimmune Therapeutics in Q2 2023 and held it in 1 quarter.
  • Diametric Capital's Adaptimmune Therapeutics position peaked at $72.6K in Q2 2023.
  • 79 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2023.

Based on Diametric Capital's 13F filing for Q3 2023, filed 14 Nov 2023.